Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$10.28 0.32 (3.21%)
2/9/2010 4:00 PM

Incyte Corp (INCY)

CAPS Rating:
**

The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating INCY

Add Stock to Watchlist

What the Community Thinks

Total Members

212 Outperforms
23 Underperforms
 

All-Stars

65 Outperforms
10 Underperforms
 

Wall Street

11 Outperforms
1 Underperforms
 

Members bullish on INCY are also bullish on:

Members bearish on INCY are also bearish on:

Ticker Tags

Small Cap (1645), Biotechnology (220), Healthcare (711), Defensive (1457)
Suggest a tag

Incyte Corp At A Glance

Current Price: $10.28
Last Trade Time: 2/9/2010 4:00 PM
Open: $10.15
Previous Close: $9.96
Daily Range: $10.07 - $10.44
52-Week Range: $1.96 - $11.24
Volume: 1,976,744
Market Cap: $1.22B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

INCY VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Incyte Corp (INCY)

Avatar ScienceInvestor (77.24) Submitted: 3/21/08 8:59 PM

Great product line for the speculative investor. The company carries a lot of debt that will be offset with an approved drug candidate. The growth from the potential product pipeline is the attractive aspect of this security. I don't have a crystal ball, but assuming the big pipeline drugs prove ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

0

Incyte Corp (INCY)

Avatar morningstarboy (74.60) Submitted: 12/05/07 1:03 PM

As of close of business on 12/04/2007, this was a 1-star Morningstar stock that was trading at more than double it's Morningstar fair value.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 34 :   1 2 3 4 5 Next »

Recs

0

 (INCY)

Avatar fireinyoureyes (60.20) Submitted: 2/07/10 4:00 PM : Outperform Start Price: $10.21 INCY Score: 0.24

2 big deals, and potential for some more on the way, Incyte has one potential blockbuster drug with Phase 3 results coming this year for Myelofibrosis, and a potential to be used for many other cancers. Good pipeline of other drugs too.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (INCY)

Avatar RyRugrodent (< 20) Submitted: 2/05/10 11:20 AM : Outperform Start Price: $10.02 INCY Score: 1.31

With the recent deals and now some recognition, this stock could be a huge gainer!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (INCY)

Avatar WakiDay (34.81) Submitted: 1/08/10 12:27 PM : Outperform Start Price: $10.86 INCY Score: 0.72

GREAT drug development stock.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (INCY)

Avatar TMFBiologyFool (95.94) Submitted: 12/21/09 4:15 PM : Underperform Start Price: $8.72 INCY Score: -21.79

$1 billion market cap is too big for the pipeline.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (INCY)

Avatar lonewulf47638 (63.75) Submitted: 12/18/09 12:04 PM : Outperform Start Price: $8.44 INCY Score: 23.92

good news today on new drug. growth will happeen soon.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 34 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 12 of 12  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLeerinkSwan 92.83 11/02/09 Outperform NS $6.01+71.05%+2.97%+68.08
TrackCowenandCo 86.76 10/28/09 Outperform NS $6.01+71.05%+1.01%+70.04
TrackStanfordRes 85.54 10/07/08 Outperform NS $5.99+71.62%+2.99%+68.63
TrackCitigroup 85.92 08/27/08 Outperform NS $9.80+4.90%-13.27%+18.17
TrackJimCramer < 20 04/24/08 Underperform 3W $11.24-8.54%-19.61%-11.07
TrackRWBaird 87.00 04/16/08 Outperform NS $10.62-3.20%-16.95%+13.75
TrackMichaelBrus 92.73 02/14/08 Outperform 1Y $12.42-17.23%-17.33%+0.10
TrackJMP 71.98 05/03/07 Outperform NS $7.91+29.96%-24.59%+54.56
TrackBofASec 94.61 01/09/07 Outperform NS $6.57+56.47%-19.44%+75.91
TrackUBS 87.99 01/09/07 Outperform NS $6.59+55.99%-19.41%+75.40
TrackPiperJaff 85.79 01/08/07 Outperform NS $6.41+60.37%-19.17%+79.55

Results 1 - 12 of 12  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 890ms